Deciphering clonal heterogeneity during myeloma evolution - CRCT-Toulouse (France)

Type de poste
Durée du poste
Contrat renouvelable
Contrat non renouvelable
Date de prise de fonction
Date de fin de validité de l'annonce


Avet-Loiseau Hervé
Corre Jill
Email du/des contacts

<p><strong>Deciphering clonal heterogeneity during myeloma evolution</strong></p><p>A <u>postdoctoral position</u>, with salary funded for two years is available in the team 13 &ldquo;Oncogenomic and immunology of myeloma&rdquo; of the Cancer research Centre of Toulouse (team 13, CRCT) directed by Pr Avet-Loiseau.</p><p>The candidate will investigate clonal heterogeneity in multiple myeloma during disease evolution.</p><p><strong>Profile </strong></p><p>We seek a highly motivated scientist that hold a Ph.D in biology or bioinformatics, with a strong background in bioinformatics or biology. Single cell analysis skills would be a clear advantage. Good track record, communication, technical and organizational skills are expected.</p><p>Offer The position is for 2 years, available immediately.</p><p>The application should contain a motivation letter, CV and contact details of 2 referees.</p><p><strong>The Host Institute</strong></p><p>The newly created Cancer Research Centre of Toulouse (CRCT) gathers 250 scientists from 3 public research institutions (Inserm UMR1037, Université Paul Sabatier-Toulouse III and CNRS ERL5294) that have joined their efforts to launch innovative researches against cancer.</p><p>The CRCT is equipped with the most recent technological tools and platforms including fully automated animal facility, flow cytometry platform, imaging platform, single cell sorting and next generation sequencing platform (see</p><p>Our research team is in close association with the Laboratory for Genomics in Myeloma also directed by Pr Avet-Loiseau. This Lab is the central lab for the Intergroupe Francophone du Myélome (IFM), the largest clinical cooperative group in the world. We receive about 2,500 new samples each year. For all these samples, we have a signed informed consent form authorizing the use of extra plasma cells for research purposes, including genetic testing.</p><p><strong>City</strong></p><p>Toulouse is located in Southwestern France close to the Pyrenees Mountains and Spain with flight and train connections to French and European cities. With more than 100,000 students and praised quality of life, it is ranked as one of the best place to live and study in France.</p><p><strong>Project</strong></p><p>We recently participated to the development of a targeted sequencing panel (246 genes / 14q32 translocations / SNPs). Analysis of clonal evolution in homogeneously treated patients showed no specific mutation, chemoresistance and relapse being induced by acquisition of new driver mutations but also by preexisting (sub)clonal mutations. We are now moving to Single Cell analysis in order to accurately identify which clones are responsible for poor prognosis and relapse. We plan to analyze the clonal heterogeneity at all the level (RNA, CNV, Mut, and ATAC) at the single cell level, but also at the bulk level with WGS. Integration of the data will be the major objective.</p><p><strong>Relevant publications</strong></p><p>1- Understanding the role of hyperdiploidy in high-risk myeloma prognosis: which trisomies really matter? Chretien ML,* Corre J,* Lauwers- Cances V, Magrangeas F, Cleynen A, Yon E, Hulin C, Leleu X, Orsini-Piocelle F, Blade JS, Sohn C, Karlin L,Delbrel X, Hebraud B, Roussel M, Marit G, Garderet L, Mohty M, Rodon P, Voillat L, Royer B, Jaccard A, Belhadj K, Fontan J, Caillot D, Stoppa AM, Attal M, Facon T, Moreau P, Minvielle S, Avet-Loiseau H. Blood 2015</p><p>2- Fusion gene landscape and impact in Multiple Myeloma revealed by RNA-Seq analysis of a large cohort with long follow-up A. Cleynen, R. Szalat, M. Kemal Samur, S. Robiou du Pont, C. Fontan, E. Boyle, M.L. Chretien, S. Minvielle, P. Moreau, M. Attal, G. Parmigiani, N. Munshi, J. Corre, H. Avet-Loiseau Nature Comm 2017</p><p>3- Analysis of the genomic landscape of multiple myeloma highlights novel prognostic markers and disease subgroups. Bolli, N., G. Biancon, M. Moarii, S. Gimondi, Y. Li, C. de Philippis, F. Maura, V. Sathiaseelan, Y. T. Tai, L. Mudie, S. O&#39;Meara, K. Raine, J. W. Teague, A. P. Butler, C. Carniti, M. Gerstung, T. Bagratuni, E. Kastritis, M. Dimopoulos, P. Corradini, K. Anderson, P. Moreau, S. Minvielle, P. J. Campbell, E. Papaemmanuil, H. Avet-Loiseau and N. C. Munshi Leukemia 2017</p><p>4- Multiple myeloma clonal evolution in homogeneously treated patients Jill Corre, Alice Cleynen, Sébastien Robiou du Pont, Laure Buisson, Niccolo Bolli, Michel Attal, Nikhil Munshi, Hervé Avet-Loiseau Leukemia 2018</p><p><strong>Contact :</strong> Pr Hervé Avet-Loiseau Tel. : +33(0) 5 31 15 61 42 ; Email :</p><br/>
Laboratoire: Institut Universitaire du Cancer